Aurorix : Generic name : MoclobemideSNAPE, M; MALLARKEY, G.Current therapeutics. 1996, Vol 37, Num 5, pp 87-88, issn 0311-905XArticle

Clinical pharmacokinetics of the monoamine oxidase-A inhibitor moclobemideMAYERSOHN, M; GUENTERT, T. W.Clinical pharmacokinetics. 1995, Vol 29, Num 5, pp 292-332, issn 0312-5963Article

Preclinical profile of befloxatone, a new reversible MAO-A inhibitorCURET, O; DAMOISEAU-OVENS, G; SAUVAGE, C et al.Journal of affective disorders. 1998, Vol 51, Num 3, pp 287-303, issn 0165-0327Article

A double-blind randomized placebo-controlled study of the efficacy and safety of pirlindole, a reversible monoamine oxidase A inhibitor, in the treatment of depressionDE WILDE, J. E; GEERTS, S; VAN DORPE, J et al.Acta psychiatrica Scandinavica. 1996, Vol 94, Num 6, pp 404-410, issn 0001-690XArticle

Dextrométhorphane : Vickx toux sèche : capsules de suspension buvable = Dextromethorphan : Vicks toux seche® : capsules of drinkable suspensionLa Revue Prescrire. 1996, Vol 16, Num 166, issn 0247-7750, p. 690Article

RS-8359, a putative candidate for the treatment of depressionMONTGOMERY, Stuart A.International clinical psychopharmacology. 1997, Vol 12, issn 0268-1315, 38 p., SUP5Serial Issue

Species differences in enantioselective 2-oxidations of RS-8359, a selective and reversible MAO-A inhibitor, and cinchona alkaloids by aldehyde oxidaseITOH, Kunio; YAMAMURA, Mayumi; TAKASAKI, Wataru et al.Biopharmaceutics & drug disposition. 2006, Vol 27, Num 3, pp 133-139, issn 0142-2782, 7 p.Article

Treatment of comorbid opiate addiction and attention-deficit hyperactivity disorder (residual type) with moclobemide. A case reportVAIVA, Guillaume; DE CHOULY DE LENCLAVE, Marie Bérengère; BAILLY, Daniel et al.Progress in neuro-psychopharmacology & biological psychiatry. 2002, Vol 26, Num 3, pp 609-611, issn 0278-5846Article

Novel neuroprotective anti-Alzheimer drugs with anti-depressant activity derived from the anti-Parkinson drug, rasagiline : Interventions, Part IIIYOUDIM, Moussa B. H; WEINSTOCK, Marta.Mechanisms of ageing and development. 2002, Vol 123, Num 8, pp 1081-1086, issn 0047-6374Conference Paper

The effects of trazodone on sleep disturbances induced by brofaromineHAFFMANS, P. M. J; VOS, M. S.European psychiatry. 1999, Vol 14, Num 3, pp 167-171, issn 0924-9338Article

Clinical pharmacology of befloxatone : a brief reviewROSENZWEIG, P; PATAT, A; CURET, O et al.Journal of affective disorders. 1998, Vol 51, Num 3, pp 305-312, issn 0165-0327Article

Pharmacotherapy of dysthymic and chronic depressive disorders : overview with focus on moclobemideVERSIANI, M.Journal of affective disorders. 1998, Vol 51, Num 3, pp 323-332, issn 0165-0327Article

Double-blind randomized controlled study of the efficacy and tolerability of two reversible monoamine oxidase a inhibitors, pirlindole and moclobemide, in the treatment of depressionTANGHE, A; GEERTS, S; VAN DORPE, J et al.Acta psychiatrica Scandinavica. 1997, Vol 96, Num 2, pp 134-141, issn 0001-690XArticle

Moclobemide in social phobia : A controlled dose-response trialNOYES, R. JR; MOROZ, G; LYDIARD, R. B et al.Journal of clinical psychopharmacology. 1997, Vol 17, Num 4, pp 247-254, issn 0271-0749Article

Modification of the cardiovascular effects of ephedrine by the reversible monoamine oxidase A-inhibitor MoclobemideDINGEMANSE, J; GUENTERT, T; GIESCHKE, R et al.Journal of cardiovascular pharmacology. 1996, Vol 28, Num 6, pp 856-861, issn 0160-2446Article

Responders and non-responders to drug treatment in social phobia : differences at baseline and prediction of responseSLAAP, B. R; VAN VLIET, I. M; WESTENBERG, H. G. M et al.Journal of affective disorders. 1996, Vol 39, Num 1, pp 13-20, issn 0165-0327, 7 p.Article

CHF3381, a novel antinociceptive agent, attenuates capsaicin-induced pain in ratsBASSANI, Franco; BERGAMASCHI, Marco; BOLZONI, Pier Tonino et al.European journal of pharmacology. 2005, Vol 519, Num 3, pp 231-236, issn 0014-2999, 6 p.Article

Death following acute poisoning by moclobemideGIROUD, Christian; HORISBERGER, Beat; CHIN EAP et al.Forensic science international. 2004, Vol 140, Num 1, pp 101-107, issn 0379-0738, 7 p.Article

Non-MAO A binding of clorgyline in white matter in human brainFOWLER, J. S; LOGAN, J; FELDER, C et al.Journal of neurochemistry. 2001, Vol 79, Num 5, pp 1039-1046, issn 0022-3042Article

The effect of augmentation with moclobemide on symptoms of schizophreniaSILVER, H; AHARON, N; HAUSFATER, N et al.International clinical psychopharmacology. 1999, Vol 14, Num 3, pp 193-195, issn 0268-1315Article

Anxiolytic and memory improving effects of moclobemideNOWAKOWSKA, E; CHODERA, A; KUS, K et al.Arzneimittel-Forschung. 1998, Vol 48, Num 6, pp 625-628, issn 0004-4172Article

Epidemiology and relative toxicity of antidepressant drugs in overdoseHENRY, J. A.Drug safety. 1997, Vol 16, Num 6, pp 374-390, issn 0114-5916Article

Social phobia : the need for treatmentMONTGOMERY, S. A.International clinical psychopharmacology. 1997, Vol 12, pp S3-S9, issn 0268-1315, SUP6Conference Paper

Safety, tolerability and efficacy of the reversible monoamine oxidase inhibitor RS-8359 in early clinical trialsPÜCHLER, K; PLENKER, A; VOLZ, H.-P et al.International clinical psychopharmacology. 1997, Vol 12, pp S31-S36, issn 0268-1315, SUP5Article

A case of serotonin syndrome induced by moclobemide during an extreme heatwaveBUTZKUEVEN, H.Australian and New Zealand journal of medicine. 1997, Vol 27, Num 5, pp 603-604, issn 0004-8291Conference Paper